Big changes forecast for pharma

6 November 2006

Lyon, France-based-Allbizreport.com has released a new pharmaceutical market research report, which provides five key predictions for the trends that will shape the pharmaceutical market in 2007 and beyond, and explains the impact of these forecasts on the industry.

Predictions discussed include the continued influence of M&A and licensing, the increasing impact of cost containment policies by payers and an increasing reliance on biologics to drive growth. Within the next five years, an estimated $80.0 billion in 2005 product sales will be exposed to generic competition.

While the specialty pharmaceutical sector has traditionally capitalized on opportunities from Big Pharma, competitive pressure and the maturing market is forcing them to develop new specialization strategies. These pressures, such as commoditization of drug-delivery technologies and competition from foreign bulk generics manufacturers, are driving new company growth models and a focus on targeted portfolios, stronger late-stage drug development capabilities, M&A and in-licensing activity, the report says.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight